Life sciences companies (particularly early stage companies) may be attracted to an LLC holding company structure as an alternative to a typical C corporation structure to maximize both the purchase ...

Pharma innovators have long pursued a variety of deal structures to navigate the risks associated with the drug development process. Here we explore the legal and regulatory dynamics of these creative ...

Life sciences had a rough 2025 — the least active IPO market in over a decade — but AI adoption across the sector accelerated anyway. Problem is, the governance infrastructure is still being built ...

It’s no longer a question if these companies will grow; it’s about how and where they choose to grow to offer flexibility, ...

October 09, 2025 - Big Pharma continues its hunt for innovation, and with uncertain market and regulatory conditions, some life sciences companies may be feeling the pressure to make their M&A exit or ...

If NIH prioritizes human-based science in its ongoing overhaul of biosafety policies, the oversight system that has evolved for review of a wide-swath of biological research could atrophy and expose ...